Healthcare News Weekly Roundup: June 21–27, 2026 | FDA Approvals, AbbVie’s $10.9B Deal, EMA Revocations, and NHS Pay Dispute Breakthrough

The week of 21st–27th June 2026, produced one of the most consequential seven-day stretches in global healthcare this year. At the center of it all: the FDA’s June 24 decision to approve Gilead’s Trodelvy in combination with Merck’s Keytruda as a first-line treatment for metastatic triple-negative breast cancer, a decision that fundamentally reorders treatment strategy for a cancer subtype affecting an estimated 15% of all breast cancer patients and long overdue for a meaningful frontline advance.

The same week, AbbVie announced a $10.9 billion all-cash acquisition of Apogee Therapeutics, the largest pharma buyout of 2026’s second quarter; Ionis Pharmaceuticals secured expanded FDA approval for Tryngolza as the only therapy proven to reduce acute pancreatitis risk in severe hypertriglyceridemia; and Europe’s CHMP issued a rare recommendation to revoke the marketing authorization for avacopan (Tavneos) on data integrity grounds.

Here are the most significant healthcare stories shaping clinical practice, investment decisions, and health policy across the US, UK, Europe, Canada, and Australia:

• Gilead/Merck: FDA Clears Trodelvy Plus Keytruda for First-Line Metastatic TNBC
• AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Immunology Bet
• Ionis Wins Expanded FDA Approval for Tryngolza in Severe Hypertriglyceridemia
• EMA CHMP Recommends Revoking EU Authorization for Avacopan (Tavneos)
• Serapha Bio Launches with $230M to Advance Base Editing Therapy for AATD
• NHS Resident Doctors Ballot on Government Pay Offer as BMA Strikes Loom
• Replimune’s RP1 BLA Resubmission Accepted; FDA Sets August 2 Decision Date
• EMA CHMP June 2026 Meeting Delivers Six New Medicine Approvals
• US Medicaid Work Requirements Take Shape Under CMS June 2026 Guidance
• MHRA AI Regulatory Sandbox Moves Toward Implementation
• Biotech IPO Wave Continues: Kardigan Raises $400M in Cardiovascular Debut
• Biotech M&A Context: Big Pharma’s Record Deal Velocity Continues Into June

Gilead and Merck Win FDA Approval for Trodelvy Plus Keytruda in First-Line Metastatic TNBC

On June 24, 2026, the FDA approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer, marking the first time an antibody-drug conjugate has been cleared for the initial treatment of this aggressive cancer subtype.

The FDA on June 24, 2026, approved Trodelvy for two uses in adults with TNBC: as a single agent for patients who are not candidates for immunotherapy, and in combination with Keytruda or Keytruda Qlex for patients with PD-L1-positive tumors confirmed by an FDA-authorized test.

The approval was supported by data from two pivotal Phase 3 trials, ASCENT-03 and ASCENT-04/KEYNOTE-D19. TNBC accounts for approximately 15% of all breast cancers, disproportionately affecting younger, premenopausal, and Black and Hispanic women, with an average time to metastatic recurrence of approximately 2.6 years compared with 5 years for other breast cancers.

The ASCENT-04 data, presented at the 2026 ASCO Annual Meeting in Chicago, established the Trodelvy-plus-pembrolizumab combination as a meaningful advance over chemotherapy plus checkpoint inhibitor combinations in PD-L1-positive patients. Gilead Sciences

This approval was reviewed under Project Orbis, an FDA initiative that allows cancer drug approvals to be reviewed simultaneously by regulatory agencies in multiple countries, including Australia, Israel, Brazil, Canada, and Switzerland. That multi-agency coordination carries enormous practical significance: it means Trodelvy’s frontline label could be extended to patients across multiple regulatory jurisdictions within a compressed timeframe, rather than the fragmented country-by-country review processes that have historically delayed oncology access.

For oncologists, payers, and cancer advocacy organizations alike, the decision reshapes treatment pathway discussions for a patient population that has too often seen first-line failure lead to rapid disease progression and limited second-line options. Competing companies developing ADC programs for breast cancer, including AstraZeneca and Daiichi Sankyo with ENHERTU, will now need to define their differentiation from a Trop-2-directed backbone that has moved squarely into the first-line standard of care conversation.

Source: Gilead Sciences | https://investors.gilead.com/news/news-details/2026/U-S–FDA-Approves-Trodelvy-for-First-Line-Treatment-of-Metastatic-Triple-Negative-Breast-Cancer/default.aspx

AbbVie Acquires Apogee Therapeutics for $10.9 Billion, Deepening Immunology and Respiratory Portfolio

AbbVie and Apogee Therapeutics announced on June 22, 2026, that they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis and asthma, with Apogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

The proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases. Apogee’s lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis. Apogee’s pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin, being developed in asthma.

Zumilokibart achieved significant week-16 skin clearance in about two-thirds of Phase 2 patients with concomitant itch and disease-control improvements, and extended-interval maintenance regimens were supported by longer-term Phase 2 data, with a safety profile consistent with the IL-13-targeting class.

The transaction, which the boards of both companies unanimously approved, is expected to close in the third quarter of 2026 pending shareholder approval and regulatory clearance. AbbVie’s $10.9 billion acquisition of Apogee Therapeutics is the year’s second-largest biotech buyout and the company’s biggest since its $63 billion takeover of Allergan in 2019.

From a competitive positioning standpoint, this deal matters beyond the specific assets involved. Dupixent, Sanofi and Regeneron’s IL-4/IL-13 biologic, has dominated the atopic dermatitis market for years. A half-life-extended IL-13 antibody that can be dosed quarterly or twice yearly — backed by AbbVie’s commercial infrastructure — represents a direct attempt to compete on dosing convenience in a patient population that has demonstrated strong preferences for less frequent injection schedules. The immunology pipeline expansion also reduces AbbVie’s long-term dependence on its TNF inhibitor legacy, even as Skyrizi and Rinvoq continue to perform well in the market.

Source: AbbVie Newsroom | https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio

Ionis Wins FDA Approval for Tryngolza as First Therapy to Reduce Acute Pancreatitis Risk in Severe Hypertriglyceridemia

On June 24, 2026, Ionis Pharmaceuticals announced that the FDA approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: triglycerides greater than or equal to 500 mg/dL), available in 50 mg or 80 mg doses self-administered once monthly via an autoinjector.

The significance of this decision lies in what it achieves that decades of available lipid-lowering agents could not. The approval is notable because existing approved triglyceride-lowering therapies, including fibrates, omega-3 fatty acids, and niacin, have not demonstrated a reduction in acute pancreatitis risk in controlled trials. The expanded indication was supported by data from two Phase 3 trials: CORE (617 participants) and CORE2 (446 participants).

Across both trials, placebo-adjusted fasting triglyceride reductions at 6 months were approximately 49% to 63% for the 50 mg dose and 55% to 72% for the 80 mg dose, sustained to 12 months, and acute pancreatitis events fell substantially, with a pooled rate ratio of 0.15, and 86% of patients achieved triglycerides below 500 mg/dL.

The expanded indication extends olezarsen’s use to the broader sHTG population, which Ionis estimates at more than 3 million people in the US, following its earlier approval for familial chylomicronemia syndrome, a much rarer monogenic form. That population difference is commercially decisive: moving from an ultra-rare orphan indication to a prevalent condition positions Tryngolza as what Ionis leadership described as a potential blockbuster.

The drug’s mechanism, inhibiting apolipoprotein C-III production via antisense oligonucleotide technology, represents a distinct class from existing lipid-lowering approaches, and analysts will now watch closely whether commercial execution, payer coverage negotiations, and formulary positioning can convert a strong PDUFA outcome into durable revenue growth that carries Ionis toward the cash flow breakeven it has targeted for 2028.

Source: Ionis Pharmaceuticals | https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-approved-fda-first-and-only-treatment

EMA Recommends Revoking EU Marketing Authorization for Tavneos (Avacopan) Over Pivotal Trial Data Integrity Failure

In one of the most consequential regulatory decisions from Europe this week, the EMA’s CHMP formally recommended the revocation of the EU marketing authorization for Tavneos (avacopan), marketed by Vifor Fresenius Medical Care Renal Pharma and developed by CSL, for the treatment of ANCA-associated vasculitis.

After reviewing the totality of the available data and new information on how the study data were handled, the CHMP concluded that the ADVOCATE study, the pivotal trial on which the original marketing authorization was based, was conducted in breach of good clinical practice principles.

The CHMP is recommending that no new patients should start treatment with Tavneos, and that existing patients should be switched to suitable alternatives. As Tavneos is associated with an increased risk of drug-induced liver injury and vanishing bile duct syndrome, including cases with a fatal outcome, the liver function of patients treated with Tavneos should be closely monitored until treatment is permanently stopped.

As Amgen prepares to defend Tavneos’ market approval in the US, the company has received a bad omen overseas, with European regulators recommending that the ANCA-associated vasculitis drug lose its authorization following a new review that concluded its benefits are no longer proven to outweigh its risks. Amgen’s US regulatory situation is distinct from the EMA process, but the EU revocation recommendation will intensify scrutiny of the ADVOCATE trial data on both sides of the Atlantic.

For the small but acutely affected patient population living with granulomatosis with polyangiitis or microscopic polyangiitis, this decision creates urgent clinical management questions, as avacopan has been positioned as a more targeted complement to standard immunosuppression than high-dose corticosteroids. Clinicians managing these patients in the EU will need to act quickly on transition planning while awaiting the European Commission’s formal decision.

Source: European Medicines Agency | https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos

EMA CHMP June 2026 Meeting Delivers Six New Medicine Approvals, Including Parkinson’s and Influenza Vaccine

Beyond the Tavneos revocation, the CHMP’s June 22–25 plenary produced a substantive slate of positive outcomes across therapeutic areas. The committee recommended granting a marketing authorization for Aujemflu, a vaccine to protect people aged 50 years and older against influenza; Hopledo (levodopa/carbidopa), for the treatment of adults with Parkinson’s disease and moderate-to-severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase inhibitor-based regimens; and Onswik (insulin efsitora alfa) for the treatment of type 2 diabetes mellitus in adults. The committee also adopted positive opinions for two biosimilar medicines.

The CHMP reversed its earlier negative opinion on Acadia Pharmaceuticals’ trofinetide (Daybu), recommending marketing authorization for the treatment of neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older. The reversal for Daybu is particularly significant: Rett syndrome is a rare, severe neurodevelopmental disorder affecting primarily girls, with limited approved therapies globally. Acadia’s successful re-examination of a prior negative opinion will be closely studied by other sponsors who have faced initial CHMP rejections.

Hopledo will be available in four modified-release hard capsule strengths from Zambon S.p.A., combining immediate-release granules and extended-release beads, targeting patients with Parkinson’s disease whose motor fluctuations have not been adequately controlled on existing oral regimens.

The modified-release design addresses one of the persistent challenges of levodopa therapy in advanced Parkinson’s: “off” periods and unpredictable motor swings that erode quality of life. For the roughly 1.2 million people living with Parkinson’s disease across Europe, the Hopledo approval adds a formulation option that could reduce dosing frequency burden for a segment of patients who currently manage multiple daily doses.

Source: European Medicines Agency | https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2026

Serapha Bio Launches with $230 Million to Advance In Vivo Base Editing Therapy for Alpha-1 Antitrypsin Deficiency

Boundless Bio and Serapha Bio announced on June 23, 2026, a definitive all-stock merger agreement, with the combined company to operate as Serapha Bio and advance Serapha’s in vivo base editing program for Alpha-1 Antitrypsin Deficiency, supported by a concurrent $230 million private placement co-led by RTW Investments and RA Capital Management.

Serapha’s lead program, SERP-01, is an in vivo base editing program developed in China and licensed from YolTech Therapeutics, investigating a potential treatment for alpha-1-antitrypsin deficiency targeting the SERPINA1 E342K (PiZZ) mutation. Patients with AATD are unable to produce sufficient, properly formed levels of the AAT protein, which is generated by the liver to protect the lungs from inflammation and damage. Serapha’s $230 million fundraise consists of a $138 million Series A plus $92 million in additional funds expected to close upon finalization of the merger, with proceeds expected to propel operations into the second half of 2029, enabling completion of Phase 2 testing and initiation of Phase 3.

The AATD field has attracted intense competition in 2026, and Serapha’s in vivo base editing approach represents a distinct strategic bet compared with protein replacement therapies or gene transfer approaches already in the pipeline. The ability to demonstrate proof-of-concept restoration of serum AAT to normal levels from a single base edit differentiates the candidate on durability grounds.

From a deal-structure perspective, the YolTech licensing arrangement, which includes potential regulatory and commercial milestones of over $2 billion, reflects a pattern of Western biotechs accessing Chinese-originated assets that has accelerated significantly across 2025 and 2026. The emergence of STAT News-reported investor syndicate members, including Janus Henderson, Vivo Capital, and Balyasny, underscores that this transaction crossed the threshold of credibility with institutional money that treats AATD as a high-conviction rare disease commercial opportunity.

Source: GlobeNewswire / Boundless Bio | https://www.globenewswire.com/news-release/2026/06/23/3315846/0/en/boundless-bio-and-serapha-bio-announce-merger-agreement-and-230-million-concurrent-private-placement.html

NHS Resident Doctors Ballot on Government Pay Offer as BMA Membership Decides Whether to End Two-Year Dispute

The longest-running industrial dispute in modern NHS history reached a pivotal inflection point this week as the British Medical Association’s Resident Doctors Committee presented a government pay offer to a membership ballot. The BMA UK Resident Doctors Committee voted to call off strike action that had been scheduled for June 15–19, giving members the opportunity to vote on the offer. The referendum opened at 3 pm on Thursday, June 18, and closed at noon on Friday, June 26, 2026, covering all resident doctor members with NHS employment in England, locum residents, and final-year medical students.

The offer, in combination with DDRB recommendations, provides an average 6.6% pay uplift, fully delivered by April 2027. Depending on the nodal point, pay increases from April 2026 range between 3.5% and 7.1%, with a further 5.3% band from April 2027, alongside reimbursement of Royal College exam fees, reform of less-than-full-time training progression, and substantive (permanent) employment contracts for locally employed doctors from August 2026.

The dispute centers on claims that resident doctors’ salaries have suffered a substantial real-terms decline over the past 15 years, with the BMA arguing that doctors’ pay has effectively fallen by around 26% since 2008–09 once inflation is taken into account. Whether this offer translates to membership ratification or another rejection will directly determine whether the NHS enters the second half of 2026 with workforce stability or faces continued appointment disruption as autumn demand builds.

The structural stakes extend beyond pay: the offer includes up to 4,500 additional specialty training places, addressing a documented bottleneck in career progression that has driven emigration of UK-trained doctors to Australia, Canada, and the Middle East. Patient advocacy groups and hospital trust executives alike will be watching the vote outcome closely, as any continuation of industrial action through autumn would compound the NHS’s existing elective care backlog.

Source: BMA (British Medical Association) | https://www.bma.org.uk/our-campaigns/resident-doctor-campaigns/pay-in-england/government-offer-to-resident-doctors-in-england-to-end-the-dispute-on-jobs-and-pay-june-2026

Replimune’s RP1 BLA Resubmission Accepted by FDA; Advisory Committee Meeting Set for Late July

Replimune Group announced on June 26, 2026, that the FDA had accepted for review the resubmission of the Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma, with the FDA considering this a complete, class 1 response with a goal date of August 2, 2026, and notifying the company to expect an advisory committee meeting in late July.

Melanoma is the fifth most common cancer in the United States, with approximately 112,000 new cases estimated in 2026, and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Standard of care therapy includes immune checkpoint blockade, to which approximately half of patients will not respond or will progress after treatment, leaving a significant population in need of effective therapeutic alternatives. This marks the company’s third BLA submission for RP1, following an initial complete response letter in July 2025, with the resubmission seeking accelerated approval based on data from the Phase 2 IGNYTE trial in patients progressing on prior anti-PD-1 therapy.

The classification of the resubmission as a class 1 response, implying the FDA found the submitted materials sufficient to warrant full review within a compressed two-month window, signals that Replimune’s responses to the previous complete response letter were substantively adequate.

The requirement for an advisory committee meeting nonetheless indicates the agency will seek external expert input on the benefit-risk profile, particularly given the accelerated approval pathway and the Phase 2 evidentiary basis. The August 2 PDUFA date positions RP1 as one of the most closely watched oncology decisions of the summer, with the oncolytic immunotherapy field watching for signals about the FDA’s appetite for approvals in the post-PD-1 second-line melanoma space.

Source: Replimune Group | https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-acceptance-rp1-biologics-license

US Medicaid Work Requirements Gain Definition as CMS Releases June 2026 Implementation Guidance

The implementation architecture for Medicaid community engagement requirements under the One Big Beautiful Bill Act took clearer shape this week as the Centers for Medicare and Medicaid Services released additional guidance dated June 2026, expanding on initial CMS guidance issued in December 2025.

The Congressional Budget Office estimates that implementation of work requirements will reduce Medicaid spending by $344 billion over 10 years and cause 11.8 million people to lose Medicaid coverage due to H.R. 1 over the next 10 years, with 4.8 million of those losses attributable specifically to the work requirement provisions.

The June 2026 interim final rule defined medical frailty more narrowly than many states and stakeholders had expected, adding the requirement that medically frail individuals must demonstrate impaired ability to conduct work activities in addition to holding a qualifying condition, a definition that will pose barriers to Medicaid coverage and introduce additional administrative burden for states, individuals, and providers. Nebraska became the first state to implement work requirements in May 2026, with states required by statute to implement by January 1, 2027, though states may act sooner through 1115 waivers.

The gap between statutory intent and regulatory operationalization matters acutely here. By narrowing the medical frailty exemption, the June guidance creates a scenario in which individuals with documented chronic conditions, including many patients with behavioral health diagnoses, diabetes-related disability, or moderate functional impairment, may face coverage interruptions not because they chose not to work, but because the administrative apparatus around proving medical frailty is both complex and burdensome.

Hospitals with significant Medicaid patient volumes will need to factor potential coverage loss into their financial modeling for fiscal year 2027, and community health centers that serve as safety-net providers for low-income populations are already examining how staffing and service delivery models will need to adapt.

Source: Center for Health Care Strategies | https://www.chcs.org/resource/a-summary-of-national-medicaid-work-requirements/

MHRA AI Regulatory Sandbox Advances Toward Summer Implementation

The United Kingdom’s Medicines and Healthcare products Regulatory Agency continued preparations this week to operationalize its AI regulatory sandbox, which was formally announced during London Tech Week on June 9, 2026. The programme will explore how AI can improve the assessment of accuracy and safety, better predict risks, and detect effects that existing approaches may not capture, with adverse drug reactions sending around 250,000 people to hospital in the UK every year, costing the NHS over £2 billion annually.

Up to five AI-driven approaches will be tested in the first phase, with the MHRA beginning work with industry and academic partners from summer 2026 to shape how the sandbox operates. The regulatory significance of this initiative extends well beyond the UK. The aligned pathway, launched on April 1, 2026, as part of the government’s 10 Year Health Plan and Life Sciences Sector Plan, enables NICE to deliver its technology appraisal guidance simultaneously with the MHRA’s marketing authorization decision, potentially bringing new medicines to NHS patients three to six months sooner. Twenty-seven pharmaceutical companies have registered as early adopters.

The MHRA sandbox structure is notable precisely because it inverts the conventional regulatory dynamic: rather than companies developing AI tools and then seeking post-hoc regulatory validation, the sandbox creates a controlled environment where AI developers and regulators co-design the evidence standards that will govern eventual approval. That model, if successfully implemented, could give the UK a meaningful first-mover advantage in attracting AI-driven drug development infrastructure, particularly as the FDA and EMA both develop their own frameworks for evaluating AI tools in clinical and regulatory contexts. For health systems, pharmaceutical sponsors, and digital health developers globally, the summer 2026 timeline for the MHRA sandbox marks an important proof-of-concept moment.

Source: UK Government / MHRA | https://www.gov.uk/government/news/mhra-launches-ai-sandbox-to-accelerate-medicines-development-and-improve-safety

Kardigan Raises $400 Million in Cardiovascular IPO, Extending 2026 Biotech Offering Streak

Cardiovascular drug startup Kardigan priced a $400 million initial public offering, making it the fourth drug startup in 2026 to raise at least $400 million in IPO proceeds, a total rarely seen since 2021, according to BioPharma Dive data, with the offering lifting the median amount raised by the 2026 class to almost $302 million, well beyond what had been seen over the previous five years.

Kardigan was founded by former executives of MyoKardia, the biotech that developed the cardiac myosin inhibitor Camzyos, acquired by Bristol Myers Squibb for $13 billion. The company’s pipeline includes danicamtiv, an oral myosin activator being tested for genetic dilated cardiomyopathy in the Phase 2b/3 KINSHIP-DCM study with topline data expected in the first half of 2027; ataciguat, a soluble guanylate cyclase activator for calcific aortic valve stenosis; and tonlamarsen, an antisense oligonucleotide for acute severe hypertension. All three programs target conditions with no currently approved therapies, positioning Kardigan as a precision cardiovascular platform rather than a me-too entrant.

The Kardigan IPO’s significance lies partly in what it reveals about investor appetite in mid-2026: public markets are rewarding late-stage cardiovascular biotechs with established management pedigrees and clear data catalysts, rather than funding broad early-stage exploration. Including Kardigan, four biotechs in 2026 have raised at least $400 million in IPO proceeds, the most in a single year since 2021, with total tracked IPO proceeds reaching roughly $5 billion across US-listed biotech IPOs. The pattern also reflects that the biotech IPO recovery remains selective: the 2026 class skews heavily toward Phase 2 or Phase 3 programs, and median raise sizes suggest institutional investors are committing meaningfully when the risk profile is right, not simply chasing the IPO window.

Source: BioPharma Dive | https://www.biopharmadive.com/news/kardigan-ipo-price-biotech-myokardia-heart-drugs/822947/

Key Healthcare Deals and Approvals: 21st–27th June 2026

Closing Section

The week of 21st–27th June 2026, demonstrated that the global healthcare system is simultaneously expanding patient access at the frontline of cancer care, tightening data integrity standards for approved medicines, and debating the structural conditions under which vulnerable populations can maintain insurance coverage.

The Trodelvy plus Keytruda approval in metastatic TNBC, the Tryngolza expanded label, AbbVie’s Apogee acquisition, and the EMA’s Tavneos revocation recommendation arrived within 48 hours of each other, creating a composite picture of a regulatory environment that is both productive and uncompromising.

Stay tuned for next week’s healthcare news roundup, covering FDA advisory committee outcomes, NHS pay ballot results, and the latest from global biotech pipelines.